Skip to main content
Erschienen in: Community Mental Health Journal 8/2018

03.08.2018 | Original Paper

Five Year Outcomes of Tapering Antipsychotic Drug Doses in a Community Mental Health Center

verfasst von: Sandra Steingard

Erschienen in: Community Mental Health Journal | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

There is evidence that many individuals are on higher doses of antipsychotic drug than is required for optimal functioning yet there are limited guidelines on how to reduce them. This paper reports on 5 year outcomes for sixty-seven individuals who received treatment at a community mental health center and were offered the opportunity to gradually reduce their doses of antipsychotic drug in collaboration with the treating psychiatrist. Over a period of 6 months, the author invited patients who were clinically stable and able to participate in discussions of potential risks and benefits to begin gradual dose reductions. Initially, 40 expressed interest in tapering and 27 declined. The groups did not differ in age, sex, race, or diagnosis. The group who chose to taper began on significantly lower doses. Most patients succeeded at making modest dose reductions. At 5 years, there were no significant differences in the two outcomes measures, rate of hospitalization and employment status. Many patients were able to engage in these discussions which did not result in widespread discontinuation of drug. This is a naturalistic, small study of a topic that warrants further research.
Literatur
Zurück zum Zitat Association, A. P. (2006). American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006: American Psychiatric Pub. Association, A. P. (2006). American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006: American Psychiatric Pub.
Zurück zum Zitat Association, C. P. (2005). Clinical practice guidelines: Treatment of schizophrenia. Canadian Journal of Psychiatry, 50(13), 7S. Association, C. P. (2005). Clinical practice guidelines: Treatment of schizophrenia. Canadian Journal of Psychiatry, 50(13), 7S.
Zurück zum Zitat Chouinard, G., Samaha, A. N., Chouinard, V. A., Peretti, C. S., Kanahara, N., Takase, M., & Iyo, M. (2017). Antipsychotic-induced dopamine supersensitivity psychosis: Pharmaacolgy, criteria, and therapy. Psychotherapy and Psychosomatics, 86, 189–219.CrossRef Chouinard, G., Samaha, A. N., Chouinard, V. A., Peretti, C. S., Kanahara, N., Takase, M., & Iyo, M. (2017). Antipsychotic-induced dopamine supersensitivity psychosis: Pharmaacolgy, criteria, and therapy. Psychotherapy and Psychosomatics, 86, 189–219.CrossRef
Zurück zum Zitat Goff, D. C., Falkai, P., Fleischhacker, W., Girgis, R. R., Kahn, R. M., Uchida, H., et al. (2017). The long-term effects of antipsychotic medication on clinical course in schizophrenia. American Journal of Psychiatry, 174(9), 840–849.CrossRef Goff, D. C., Falkai, P., Fleischhacker, W., Girgis, R. R., Kahn, R. M., Uchida, H., et al. (2017). The long-term effects of antipsychotic medication on clinical course in schizophrenia. American Journal of Psychiatry, 174(9), 840–849.CrossRef
Zurück zum Zitat Harding, C., Brooks, G. W., Ashikaga, T., Strauss, J. S., & Breier, A. (1987). The Vermont longitudinal study of persons with severe mental illness,II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry, 144(6), 727–735.CrossRef Harding, C., Brooks, G. W., Ashikaga, T., Strauss, J. S., & Breier, A. (1987). The Vermont longitudinal study of persons with severe mental illness,II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry, 144(6), 727–735.CrossRef
Zurück zum Zitat Harrow, M., Jobe, T. H., Faull, R. N., & Yang, J. (2017). A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Research, 256, 267–274.CrossRef Harrow, M., Jobe, T. H., Faull, R. N., & Yang, J. (2017). A 20-year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia. Psychiatry Research, 256, 267–274.CrossRef
Zurück zum Zitat Lerner, P. P., Miodownik, C., & Lerner, V. (2015). Tardive dyskinesia (syndrome):current concept and modern approaches to its management. Psychiatry and Clinical Neurosciences, 69(6), 321–334.CrossRef Lerner, P. P., Miodownik, C., & Lerner, V. (2015). Tardive dyskinesia (syndrome):current concept and modern approaches to its management. Psychiatry and Clinical Neurosciences, 69(6), 321–334.CrossRef
Zurück zum Zitat Leucht, S., Komossa, T. M., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063–2207.CrossRef Leucht, S., Komossa, T. M., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063–2207.CrossRef
Zurück zum Zitat Olfson, M., Gerhard, T., & Huang, C. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72(12), 1172–1181.CrossRef Olfson, M., Gerhard, T., & Huang, C. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72(12), 1172–1181.CrossRef
Zurück zum Zitat Pramyothin, P. (2010). KhaodhiarL: Metabolic syndrome with the atypical antipsychotics. Current Opinion in Endocrinology, Diabetes and Obesity, 17(5), 460–466.CrossRef Pramyothin, P. (2010). KhaodhiarL: Metabolic syndrome with the atypical antipsychotics. Current Opinion in Endocrinology, Diabetes and Obesity, 17(5), 460–466.CrossRef
Zurück zum Zitat Robinson, D. G., Schooler, N. R., John, M., Correll, C. U., Marcy, P., Addington, J. et al. (2015). Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: Data from the national RAISE-ETP study. American Journal of Psychiatry, 172(3), 237–248.CrossRef Robinson, D. G., Schooler, N. R., John, M., Correll, C. U., Marcy, P., Addington, J. et al. (2015). Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: Data from the national RAISE-ETP study. American Journal of Psychiatry, 172(3), 237–248.CrossRef
Zurück zum Zitat Viguera, A. C., Baldessarini, R. J., Hegarty, J. D., van Kammen, D. P., & Tohen, M. (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry, 54(1), 49–55.CrossRef Viguera, A. C., Baldessarini, R. J., Hegarty, J. D., van Kammen, D. P., & Tohen, M. (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry, 54(1), 49–55.CrossRef
Zurück zum Zitat Woods, S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry, 64, 663–667.CrossRef Woods, S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry, 64, 663–667.CrossRef
Zurück zum Zitat Wunderink, L., Nieboer, R. M., Wiersma, S., Sytema, S., & Nienhuis, F. J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 70(9), 913–920.CrossRef Wunderink, L., Nieboer, R. M., Wiersma, S., Sytema, S., & Nienhuis, F. J. (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: Long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 70(9), 913–920.CrossRef
Metadaten
Titel
Five Year Outcomes of Tapering Antipsychotic Drug Doses in a Community Mental Health Center
verfasst von
Sandra Steingard
Publikationsdatum
03.08.2018
Verlag
Springer US
Erschienen in
Community Mental Health Journal / Ausgabe 8/2018
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI
https://doi.org/10.1007/s10597-018-0313-1

Weitere Artikel der Ausgabe 8/2018

Community Mental Health Journal 8/2018 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.